Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

2(33.3%)

Phase 4

2(33.3%)

Phase 1

1(16.7%)

Phase 2

1(16.7%)

6Total

N/A(2)

Phase 4(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01208961Phase 2Completed

Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation

Role: collaborator

NCT02333461Not ApplicableCompleted

Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism

Role: collaborator

NCT01239004Phase 4Completed

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Role: lead

NCT00673881Phase 1Completed

ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study

Role: lead

NCT00701727Phase 4Completed

Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study

Role: lead

NCT00728299Not ApplicableCompleted

The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness

Role: lead

All 6 trials loaded